Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Allogene Therapeutics Inc (NQ: ALLO ) 2.610 +0.020 (+0.77%) Streaming Delayed Price Updated: 4:00 PM EDT, Aug 23, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings All News about Allogene Therapeutics Inc < Previous 1 2 3 4 5 6 7 8 9 Next > The Latest Analyst Ratings for Allogene Therapeutics May 04, 2023 Via Benzinga Recap: Allogene Therapeutics Q1 Earnings May 03, 2023 Via Benzinga Allogene Therapeutics Reports First Quarter 2023 Financial Results and Business Update May 03, 2023 From Allogene Therapeutics, Inc. Via GlobeNewswire Allogene Therapeutics Announces Presentation of Phase 1 Data from the ALLO-501/501A Trials in Large B Cell Lymphoma at the American Society of Clinical Oncology (ASCO) Annual Meeting April 26, 2023 From Allogene Therapeutics, Inc. Via GlobeNewswire Xerox, Hubbell, Spotify And Other Big Stocks Moving Higher On Tuesday April 25, 2023 U.S. stocks traded lower, with the Nasdaq Composite dropping around 100 points on Tuesday. Here are some big stocks recording gains in today’s session. Via Benzinga Where Allogene Therapeutics Stands With Analysts April 18, 2023 Via Benzinga 10 Analysts Have This to Say About Allogene Therapeutics March 21, 2023 Via Benzinga Allogene Therapeutics to Report First Quarter 2023 Financial Results on May 3, 2023 April 25, 2023 From Allogene Therapeutics, Inc. Via GlobeNewswire Allogene Therapeutics Appoints Timothy Moore as Chief Technical Officer April 20, 2023 From Allogene Therapeutics, Inc. Via GlobeNewswire Allogene Therapeutics Presents Interim Phase 1 Data on ALLO-316 in Renal Cell Carcinoma at the American Association of Cancer Research (AACR) Annual Meeting April 17, 2023 From Allogene Therapeutics, Inc. Via GlobeNewswire Allogene Therapeutics's Return On Capital Employed Insights March 03, 2023 Via Benzinga What 10 Analyst Ratings Have To Say About Allogene Therapeutics March 02, 2023 Via Benzinga 7 Short-Squeeze Stocks That Could Make You Rich April 13, 2023 Although moving against the grain presents its own distinct set of risks, these short-squeeze stocks may profit the contrarian. Via InvestorPlace Consolidated Communications, CRISPR Therapeutics And Other Big Stocks Moving Higher On Thursday April 13, 2023 U.S. stocks traded higher, with the Dow Jones gaining over 100 points on Thursday. Here are some big stocks recording gains in today’s session. Via Benzinga Allogene Therapeutics Announces Participation in Four Upcoming Investor Conferences April 13, 2023 From Allogene Therapeutics, Inc. Via GlobeNewswire 7 Short-Squeeze Stocks That Could Explode in April March 30, 2023 Although these short-squeeze stocks attracted bearish attention justifiably, contrarian sentiment may see them jump higher. Via InvestorPlace Allogene Therapeutics Publishes 2022 Annual Environmental, Social and Governance (ESG) Report March 30, 2023 Report Highlights Company’s Mission to Democratize Patient Access to CAR T While Maintaining Focus on Employee Engagement, Sustainability and Corporate Governance From Allogene Therapeutics, Inc. Via GlobeNewswire Short Interest Update - Monday, March 27 March 27, 2023 Although equities broadly are starting the new week higher, the most heavily shorted stocks are trading lower today. Via Talk Markets Benzinga's Top Ratings Upgrades, Downgrades For March 21, 2023 March 21, 2023 Via Benzinga Allogene Therapeutics Announces Oral Presentation of Phase 1 Data on ALLO-316 at the American Association of Cancer Research (AACR) Annual Meeting March 14, 2023 From Allogene Therapeutics, Inc. Via GlobeNewswire Cell Therapy Has Shown Near Miraculous Remission Rates In Cancer Patients, But The Growing Industry Relies On This Company – A Uniquely Positioned Ticker In The Weeds? March 08, 2023 Cell Therapy Has Shown Near Miraculous Remission Rates In Cancer Patients, But The Growing Industry Relies On This Company – A Uniquely Positioned Ticker In The Weeds? Via News Direct Topics Economy Exposures Supply Chain Cell Therapy Has Shown Near Miraculous Remission Rates In Cancer Patients, But The Growing Industry Relies On This Company – A Uniquely Positioned Ticker In The Weeds? March 08, 2023 By David Willey, Benzinga Via TheNewswire.com Topics Economy Exposures Supply Chain Cell Therapy Has Shown Near Miraculous Remission Rates In Cancer Patients, But The Growing Industry Relies On This Company – A Uniquely Positioned Ticker In The Weeds? March 07, 2023 Cryoport Inc. (NASDAQ: CYRX) provides the life sciences industry with comprehensive supply chain solutions to support vital therapeutics. Via Benzinga Allogene Therapeutics Announces Participation in Two Upcoming Investor Conferences March 02, 2023 From Allogene Therapeutics, Inc. Via GlobeNewswire Allogene Therapeutics Announces Publication of Industry-Advancing Case Study on Chromosomal Rearrangement in Molecular Therapy March 01, 2023 From Allogene Therapeutics, Inc. Via GlobeNewswire Allogene Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update February 28, 2023 From Allogene Therapeutics, Inc. Via GlobeNewswire Allogene Therapeutics to Report Fourth Quarter and Year-End 2022 Financial Results on February 28, 2023 February 21, 2023 From Allogene Therapeutics, Inc. Via GlobeNewswire Short Squeezes Have Returned in 2023 -- Here's Your Playbook February 08, 2023 We haven't seen moves like these in a couple of years, so here's what investors should know. Via The Motley Fool Allogene Therapeutics Presents Data on Dagger™, a Next Generation AlloCAR T™ Platform Technology February 01, 2023 From Allogene Therapeutics, Inc. Via GlobeNewswire Allogene Therapeutics Publishes Preclinical Data in Clinical Cancer Research Supporting DLL3 as a Potential AlloCAR T™ Target for Small Cell Lung Cancer January 25, 2023 From Allogene Therapeutics, Inc. Via GlobeNewswire < Previous 1 2 3 4 5 6 7 8 9 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.